Pisa 4-5 Dicembre2014 XXIV MITO MEETING: CONSIGLIO DIRETTIVO.

Presentazione sul tema: "Pisa 4-5 Dicembre2014 XXIV MITO MEETING: CONSIGLIO DIRETTIVO."— Transcript della presentazione:

1 Pisa 4-5 Dicembre2014 XXIV MITO MEETING: CONSIGLIO DIRETTIVO

2 153 centri MITO (Ginecologie ed Oncologie, 2 nuovi) 10 centri MITO (gruppo traslazionale) 461 soci (7 nuovi) Centri e soci Centri e soci

3 Nuovi soci MITO-group Nuovi soci MITO-group Romualdo Nieddu - Ginecologia Ospedale Oncologico Regionale “A. Businco”- Cagliari Gloria Mittica - Oncologia Medica IRCC Università degli Studi di Torino – Candiolo (To) Celeste Cagnazzo - Oncologia Medica IRCC Università degli Studi di Torino - Candiolo (To) Antonio Perrone – Ginecologia Ospedale “Vito Fazzi” – Lecce Piera Gargiulo - Oncologia Medica Università Federico II- Napoli Giuseppe Tonini- Oncologia Medica Campus Biomedico - Roma Chiara Della Pepa - Oncologia Medica Campus Biomedico - Roma

4 MITO Pub  Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M. Gynecol Oncol. 2014 Oct 2. pii: S0090- 8258(14)01344-4.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. Incorporation of pazopanib in maintenance therapy of ovarian cancer. du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. J Clin Oncol. 2014 Oct 20;32(30):3374-82.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma. Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-S13. J Clin Oncol. 2014 Oct 20;32(30):3374-82.

5 MITO Pub  Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9). Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9). Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Oncology. 2014;86(5-6):351-8.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Lancet Oncol. 2014 Apr;15(4):396-405.  Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S; OCTAVIA Investigators. Eur J Cancer. 2014 Mar;50(4):862-3.

6 MITO Pub  Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24.  Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors. Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors. Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary. Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41.

7 MITO Pub  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary. Glasspool RM, Martín AG, Millan D, Lorusso D, Avall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus. Pautier P, Ji Nam E, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray- Coquard I. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma. Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9.  Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16.

8 MITO Pub  Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. Mangili G, Sigismondi C, Lorusso D, Pignata S. Clin Oncol. 2014 Sep 1;32(25):2814-5.  Progression-Free Survival by Local Investigator Versus Independent Central Review: Comparative Analysis of the AGO-OVAR16 Trial. Progression-Free Survival by Local Investigator Versus Independent Central Review: Comparative Analysis of the AGO-OVAR16 Trial. Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, Del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Gynecol Oncol. 2014 Nov 27.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. J Clin Oncol. 2014 May 1;32(13):1302-8. 18……

9 Studi in corso e in via di attivazione… Studi in corso e in via di attivazione… PROFIT /ENGOT SOLO2(Napoli) MILO(Napoli) NOVA(Milano) TRINOVA 2 (Roma) TRINOVA 3 (Roma) GCIG DESKTOP III (Napoli) ANZGOG Sintomi (Napoli) ONGOING MITO 8 ENGOT OV1 (INT Napoli) TUMORI RARI MITO 9 (Bari, ISR Milano) MITO 14-borderline (FBF Roma) MITO 15 YONDELIS (Gemelli-Roma) MITO 16a- MANGO OV 2 (INT Napoli) MITO 16b- MANGO OV 2 INT Napoli) MITO 17(INT Napoli) MITO 18 Horse (Roma Gemelli) MITO 19- Meta encefaliche (Sapienza-Roma) MITO 20 Piccole cellule (Gemelli-Roma) MITO 21 - BRCA 1 and BRCA 2 mutation carriers (Mirano) MITO 22 –Sierosi di basso grado (Napoli) MITO Cerv 2 (Napoli) TOTEM-Endometrio (Mango) MITO BEVAEND 2- Bevacizumab endometrio (Roma) EXPRESSION OVAR 4 (INT Milano)

10 Relazioni Internazionali Relazioni Internazionali GCIG Bryce, Pignata, Lorusso, Mezzanzanica, Bellati Savarese Cervix Brainstorming (Scambia, Greggi, Fagotti) Japan OCC 2015 Scambia Lorusso ENGOT Pignata, Bryce Fasi 1 Daniele Traslazionale Mezzanzanica GCA Marchetti, Salutari

11 MITO ma quanto ci costi? SEDE ANNO PERNOTTAMENTO PARTECIPANTI COSTOTOTALE ROMA 20097755.000 CATANIA 20107244.000 PISA 20115442000 NAPOLI 20118864000 RIUN D.M. + RIUN TRASL VERONA 20128058000 MILANO 20128972500 RIUN D.M. + RIUN TRASL BARI 20136155000 ROMA 20138573000 RIUN D.M. + RIUN TRASL SIRACUSA 20146053000 PISA 20147851000+1150062 500 RIUN D.M. + RIUN TRASL

12 Programma 2013-2015 Revisione statuto per votazioni Implementare il gruppo degli anatomo-patologi (Scibilia-Losito promotori) Continuare attività del gruppo qualità Elaborazione di protocolli che possano coinvolgere i radioterapisti (Savarese-Lorusso) Streaming e nuova struttura riunione MITO Programmi specifici dei vari gruppi